The 52-Week-High List: 13 Mid Cap Names On Monday
As of Monday, October 5, there are 13 Mid Cap US and Canada-listed stocks in the Trefis coverage universe trading at their 52-week highs. Mid Cap here means a market value between $10 billion and $40 billion, the upper figure excluded.
OKTA, with a market value of about $38.0 billion, is the largest company on the list; its stock is up 28.1% over the past month and up 130.0% over the past year. By sector, Health Care leads the list with 7 of the 13 names. For context, the S&P 500 is up 0.4% over the past month, including dividends.
The 10 Largest, By Market Cap
The table below shows the 10 largest of the 13 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D Return |
1W Return |
1M Return |
1Y Return |
|---|---|---|---|---|---|
| OKTA | $38.0 Bil | 3.2% | 8.0% | 28.1% | 130.0% |
| WST | $26.7 Bil | 3.2% | 0.3% | 9.9% | 38.4% |
| FFIV | $26.0 Bil | 1.0% | 5.3% | 16.9% | 40.1% |
| EXPD | $25.4 Bil | 0.9% | 2.9% | 3.7% | 59.4% |
| RBRK | $25.3 Bil | 3.5% | 8.5% | 33.1% | 46.2% |
| GH | $24.9 Bil | 5.3% | 5.6% | 16.3% | 204.6% |
| NDSN | $18.6 Bil | 0.3% | 0.9% | 5.7% | 45.8% |
| DT | $17.6 Bil | 1.5% | 4.1% | 14.1% | 20.7% |
| RVTY | $17.6 Bil | 3.8% | 4.2% | 20.5% | 72.5% |
| CRL | $14.9 Bil | 7.1% | 5.5% | 5.9% | 77.2% |
What Sits Behind The Biggest New Highs?
OKTA trades at 128.5 times trailing earnings, grew revenue 11.2% over the last twelve months and earned an operating margin of 7.7%.
West Pharmaceutical Services (WST) trades at 47.2 times trailing earnings, grew revenue 12.4% over the last twelve months and earned an operating margin of 21.7%.
Across the list, one-month moves range from +3.7% for Expeditors International of Washington (EXPD) to +59.3% for Twist Bioscience (TWST).
Over the past year, the median name here is up 72.5%.
6 of the 13 names are also S&P 500 members.
Before chasing any name on this list, ask what the company itself expects next. Our Guidance Momentum screen surfaces the stocks whose managements just raised their own outlooks.
Strength Is A Clue. It Is Not A Plan
A stock at its 52-week high has momentum on its side, and momentum is a real force. It is also the most crowded signal in the market, and what separates a run that lasts from one that tops is usually the business underneath.
Checking that business, across thousands of names, is how the Trefis High Quality (HQ) Portfolio is assembled: roughly 30 companies that pass the quality screens, rebalanced on rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Let the highs point; let the discipline decide.